公开(公告)号：EP2892525B1

公开(公告)日：2018-06-13

申请号：EP13835809.8

申请日：2013-09-10

申请人： Board of Regents of the Nevada System of Higher Education, on Behalf of the University of Nevada, Reno

发明人： BURKIN, Dean ,  WUEBBLES, Ryan

IPC分类号： A61K31/4178 ,  A61K31/422 ,  A61K31/427 ,  A61P21/04 ,  A61P21/00 ,  A61K45/06

CPC分类号： A61K31/404 ,  A61K31/16 ,  A61K31/19 ,  A61K31/20 ,  A61K31/277 ,  A61K31/341 ,  A61K31/343 ,  A61K31/36 ,  A61K31/37 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/4035 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/421 ,  A61K31/426 ,  A61K31/4365 ,  A61K31/4402 ,  A61K31/4418 ,  A61K31/444 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/496 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5365 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/541 ,  A61K31/551 ,  A61K31/57 ,  A61K31/575 ,  A61K31/661 ,  A61K38/05 ,  A61K38/39 ,  A61K45/06

摘要： Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

公开(公告)号：EP3201174A4

公开(公告)日：2018-06-06

申请号：EP15847016

申请日：2015-10-02

申请人： THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV

发明人： WU JIAN HUI ,  TIAN XIAOHONG ,  LIU WEIGUO

IPC分类号： C07C275/40 ,  A61K31/17 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/495 ,  A61K31/50 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5375 ,  A61P35/00 ,  C07D209/08 ,  C07D213/75

CPC分类号： A61K31/17 ,  A61K31/192 ,  A61K31/277 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/495 ,  A61K31/50 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5375 ,  A61K45/06 ,  C07C275/24 ,  C07C275/30 ,  C07C275/34 ,  C07C275/40 ,  C07C275/42 ,  C07D209/08 ,  C07D213/75 ,  C07D215/38 ,  C07D233/64 ,  C07D237/20 ,  C07D239/42 ,  C07D241/20 ,  C07D263/32 ,  C07D263/48 ,  C07D295/104 ,  C07D295/135 ,  C07D307/52 ,  C07D317/66 ,  C07D333/20 ,  C07D401/12 ,  C07D413/12 ,  A61K2300/00

摘要： Urea-based and bis-urea based compounds and analogues thereof are disclosed. These compounds are useful in the treatment of androgen-dependent diseases or disorders and androgen receptor-mediated diseases or disorders. Specifically, the compounds are useful in the treatment of diseases or disorders that are AR negative.

公开(公告)号：EP2641598B1

公开(公告)日：2018-06-06

申请号：EP11841251.9

申请日：2011-11-15

申请人： Posi Visionary Solutions LLP

发明人： BERNARDO ESCUDERO, Roberto ,  SAVOIR VILBOUEF, John Claude

IPC分类号： A61K31/24 ,  A61K31/80 ,  A61K38/43 ,  A61P1/00 ,  A61K9/16 ,  A61K9/20

CPC分类号： A61K38/47 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/02 ,  A61K31/05 ,  A61K31/215 ,  A61K31/235 ,  A61K31/24 ,  A61K31/404 ,  A61K31/437 ,  A61K31/439 ,  A61K31/451 ,  A61K31/5415 ,  A61K31/765 ,  A61K31/80 ,  A61K38/465 ,  A61K38/4826 ,  A61K38/4873 ,  A61K38/488 ,  A61K45/06 ,  C12Y302/01022 ,  A61K2300/00

摘要： The invention relates to a pharmaceutical formulation or composition intended to be administered orally in the form of a tablet, a coated tablet or a capsule, for the prevention or treatment of intestinal disorders, such as irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, digestive enzymes, a binding agent, a diluent, an adsorbent agent, a disintegrating agent, a lubricant and a glidant, effective for normalising colon transit, for providing an analgesic activity, for providing an antispasmodic activity and for reducing symptoms related to intestinal gas, such as distention, abdominal pain and flatulence.

公开(公告)号：EP3131582B1

公开(公告)日：2018-05-23

申请号：EP15721912.2

申请日：2015-04-14

申请人： Vertex Pharmaceuticals Incorporated

发明人： PHENIX, Brian Dean ,  BAGNOL, Laurent Jean-claude ,  BRODEUR, Geoffrey Glen ,  CHANDRAN, Sachin ,  DOKOU, Eleni ,  FERRIS, Lori Ann ,  KNEZIC, Dragutin ,  MCCARTY, Katie Lynn ,  MEDEK, Ales ,  WAGGENER, Sara A.

IPC分类号： A61K45/06 ,  A61K31/404 ,  A61K31/47 ,  C07D215/00 ,  C07D209/04 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20

CPC分类号： A61K9/14 ,  A61K9/146 ,  A61K9/16 ,  A61K9/1652 ,  A61K9/2054 ,  A61K9/2077 ,  A61K31/404 ,  A61K31/443 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K45/06 ,  C07D209/04 ,  C07D215/00 ,  C07D215/56 ,  C07D405/12 ,  A61K2300/00

摘要： The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

公开(公告)号：EP3218356A4

公开(公告)日：2018-05-16

申请号：EP15859834

申请日：2015-11-09

申请人： FORGE LIFE SCIENCE LLC

发明人： REMISZEWSKI STACY ,  KOYUNCU EMRE ,  SUN QUN ,  CHIANG LILLIAN

IPC分类号： C07D215/38 ,  A61K31/404 ,  A61K31/47 ,  A61P31/12 ,  C07D209/04 ,  C07D217/22

CPC分类号： A61K31/404 ,  A61K31/47 ,  A61P31/12 ,  C07C217/62 ,  C07C235/38 ,  C07D209/04 ,  C07D215/40 ,  C07D241/44

摘要： This document relates to compounds useful as agents for preventing or treating human cytomegalovirus (HCMV) infections.

公开(公告)号：EP3307299A1

公开(公告)日：2018-04-18

申请号：EP16730498.9

申请日：2016-06-13

申请人： Nymox Corporation

发明人： AVERBACK, Paul

IPC分类号： A61K38/17 ,  A61K38/10 ,  A61P35/00

CPC分类号： A61K38/10 ,  A61K9/0053 ,  A61K31/18 ,  A61K31/404 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/58 ,  A61K38/1709 ,  A61K45/06 ,  A61K2300/00

摘要： The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors using compounds based on small peptides in combination with additional active agent(s). The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intraprostatically, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof.

公开(公告)号：EP2914250B1

公开(公告)日：2018-04-04

申请号：EP13821931.6

申请日：2013-11-05

申请人： Commissariat à l'Énergie Atomique et aux Énergies Alternatives

发明人： PROST, Stephane ,  KIRSZENBAUM, Marek ,  LE DANTEC, Mikael ,  ROUSSELOT, Philippe ,  LEBOULCH, Philipe

IPC分类号： A61K31/00 ,  A61K31/404 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61P35/02

CPC分类号： A61K31/4439 ,  A61K31/404 ,  A61K31/426 ,  A61K31/427 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

摘要： Provided are methods for eliminating hematologic cancer stem cells in vivo, and thus preventing cancer relapse. The methods comprise a Signal Transducer and Activator of Transcription 5 (STAT5) antagonist (e.g., a PPARγ agonist) after the patient has had ana initial course of treatment with an anti-cancer agent (e.g., a TKI), to eliminate residual cancer stem cells which cause relapse.

公开(公告)号：EP3286164A1

公开(公告)日：2018-02-28

申请号：EP16783866

申请日：2016-04-21

申请人： GTX INC ,  UNIV OF TENNESSEE RESEARCH FOUNDATION

发明人： NARAYANAN RAMESH ,  MILLER DUANE D ,  PONNUSAMY THAMARAI ,  HWANG DONG-JIN ,  HE YALI ,  PAGADALA JAYAPRAKASH ,  DUKE CHARLES B ,  COSS CHRISTOPHER C ,  DALTON JAMES T

IPC分类号： C07C271/02 ,  A61K31/325 ,  A61K45/06

CPC分类号： A61K31/404 ,  A61K9/0014 ,  A61K31/403 ,  A61K31/405 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/47 ,  A61K31/472 ,  A61K45/06 ,  C07C271/02 ,  C07D209/08 ,  C07D209/42 ,  C07D215/18 ,  C07D217/04 ,  C07D231/56 ,  C07D235/16 ,  C07D487/04

摘要： This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

公开(公告)号：EP3284463A1

公开(公告)日：2018-02-21

申请号：EP17195759.0

申请日：2014-01-17

申请人： Cardioxyl Pharmaceuticals, Inc.

发明人： KALISH, Vincent Jacob ,  BROOKFIELD, Frederick Arthur ,  COURTNEY, Stephen Martin ,  FROST, Lisa Marie ,  TOSCANO, John, P.

IPC分类号： A61K31/18 ,  C07D307/64 ,  A61P9/04 ,  C07C317/14

CPC分类号： A61K31/341 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/18 ,  A61K31/222 ,  A61K31/24 ,  A61K31/255 ,  A61K31/343 ,  A61K31/381 ,  A61K31/404 ,  A61K31/42 ,  A61K31/433 ,  A61K31/4436 ,  A61K31/5377 ,  A61K31/538 ,  A61K47/12 ,  A61K47/40 ,  C07C317/14 ,  C07D307/64

摘要： The disclosed subject matter provides N- substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.

摘要翻译： 所公开的主题提供了N-取代的羟胺衍生化合物，包含此类化合物的药物组合物和试剂盒以及使用此类化合物或药物组合物的方法。 具体而言，所公开的主题提供了使用这种化合物或药物组合物治疗心力衰竭的方法。

公开(公告)号：EP3157509A4

公开(公告)日：2018-01-10

申请号：EP15809455

申请日：2015-06-18

申请人： UNIV HEALTH NETWORK

发明人： CHEN JUAN ,  ZHENG GANG ,  CUI LIYANG

IPC分类号： A61K9/107 ,  A61K9/51 ,  A61K31/337 ,  A61K31/404 ,  A61K41/00 ,  A61K47/24 ,  A61K47/42 ,  A61K47/54 ,  A61K47/60 ,  A61K47/69 ,  A61K49/00 ,  A61P35/00 ,  B82Y5/00

CPC分类号： A61K47/48807 ,  A61K9/1075 ,  A61K9/5169 ,  A61K31/337 ,  A61K31/404 ,  A61K41/0071 ,  A61K41/0076 ,  A61K47/42 ,  A61K47/48053 ,  A61K47/48069 ,  A61K47/48215 ,  A61K47/544 ,  A61K47/546 ,  A61K47/60 ,  A61K47/6907 ,  A61K47/6909 ,  A61K49/0036 ,  B82Y5/00 ,  Y10S977/773 ,  Y10S977/801 ,  Y10S977/906 ,  Y10S977/915

摘要： There is provided herein a nanovesicle comprising a monolayer of phospholipid, porphyrin-phospholipid conjugate and a peptide encapsulating a hydrophobic core, wherein the peptide comprises an amino acid sequence capable of forming at least one amphipathic α-helix; the porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain, preferably at the sn-1 or the sn-2 position, of one phospholipid; the molar % of porphyrin-phospholipid conjugate to phospholipid is 35% or less; the nanovesicle is 35 nm in diameter or less.